MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

BACKGROUND: Lung adenocarcinoma patients with EGFR gene mutations have shown a dramatic response to gefitinib. However, drug resistance eventually emerges which limits the mean duration of response. With that in view, we examined the correlations between MET gene status as assessed by fluorescence i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Noro, Rintaro, Seike, Masahiro, Zou, Fenfei, Soeno, Chie, Matsuda, Kuniko, Sugano, Teppei, Nishijima, Nobuhiko, Matsumoto, Masaru, Kitamura, Kazuhiro, Kosaihira, Seiji, Minegishi, Yuji, Yoshimura, Akinobu, Kubota, Kaoru, Gemma, Akihiko
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437672/
https://ncbi.nlm.nih.gov/pubmed/25886066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1019-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars